It’s a penny stock, says Jordan Terry in Forbes, that “could change the way cancer,
diabetes, and other horrible diseases are treated if not cured.”
I’d say such potential is worthy of notice if not investment,
and NVLX was trading earlier yesterday at a tad less than 11 cents per share.
Yahoo’s profile of NVLX reveals a little company with an
astonishing mission: to create products for enhancing the health and
well-being worldwide.
My 5-year
Yahoo chart for NVLX suggests the stock is probably in a brief pullback
from a recent runup in price and thus an opportunity for bottom feeders.
That opinion seems
to be confirmed by 3-month chart.
I bought the stock yesterday.
No comments:
Post a Comment